Emerging MEK inhibitors

James A. McCubrey, Linda S. Steelman, Steven L. Abrams, William H. Chappell, Suzanne Russo, Roger Ove, Michele Milella, Agostino Tafuri, Paolo Lunghi, Antonio Bonati, Franca Stivala, Ferdinando Nicoletti, Massimo Libra, Alberto M. Martelli, Giuseppe Montalto, Melchiorre Cervello

Research output: Contribution to journalArticle

Abstract

Importance of the field: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. Areas covered by this review: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series. What the reader will gain: By reading this review the reader will understand the important roles that genetics play in the response of patients to MEK inhibitors, the potential of combining MEK inhibitors with other types of therapy, the prevention of cellular aging and the development of cancer stem cells. Take home message: Targeting MEK has been shown to be effective in suppressing many important pathways involved in cell growth and the prevention of apoptosis. MEK inhibitors have many potential therapeutic uses in the suppression of cancer, proliferative diseases and aging.

Original languageEnglish
Pages (from-to)203-223
Number of pages21
JournalExpert Opinion on Emerging Drugs
Volume15
Issue number2
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Mitogen-Activated Protein Kinase Kinases
MAP Kinase Signaling System
Literature
Neoplastic Stem Cells
Cell Aging
Therapeutic Uses
Reading
Neoplasms
Apoptosis
Mutation
Growth

Keywords

  • Apoptosis
  • Cancer
  • ERK
  • Kinases
  • MEK
  • MEK inhibitors
  • Proliferative disorders
  • Protein phosphorylation
  • Signal transduction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., ... Cervello, M. (2010). Emerging MEK inhibitors. Expert Opinion on Emerging Drugs, 15(2), 203-223. https://doi.org/10.1517/14728210903282760

Emerging MEK inhibitors. / McCubrey, James A.; Steelman, Linda S.; Abrams, Steven L.; Chappell, William H.; Russo, Suzanne; Ove, Roger; Milella, Michele; Tafuri, Agostino; Lunghi, Paolo; Bonati, Antonio; Stivala, Franca; Nicoletti, Ferdinando; Libra, Massimo; Martelli, Alberto M.; Montalto, Giuseppe; Cervello, Melchiorre.

In: Expert Opinion on Emerging Drugs, Vol. 15, No. 2, 06.2010, p. 203-223.

Research output: Contribution to journalArticle

McCubrey, JA, Steelman, LS, Abrams, SL, Chappell, WH, Russo, S, Ove, R, Milella, M, Tafuri, A, Lunghi, P, Bonati, A, Stivala, F, Nicoletti, F, Libra, M, Martelli, AM, Montalto, G & Cervello, M 2010, 'Emerging MEK inhibitors', Expert Opinion on Emerging Drugs, vol. 15, no. 2, pp. 203-223. https://doi.org/10.1517/14728210903282760
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R et al. Emerging MEK inhibitors. Expert Opinion on Emerging Drugs. 2010 Jun;15(2):203-223. https://doi.org/10.1517/14728210903282760
McCubrey, James A. ; Steelman, Linda S. ; Abrams, Steven L. ; Chappell, William H. ; Russo, Suzanne ; Ove, Roger ; Milella, Michele ; Tafuri, Agostino ; Lunghi, Paolo ; Bonati, Antonio ; Stivala, Franca ; Nicoletti, Ferdinando ; Libra, Massimo ; Martelli, Alberto M. ; Montalto, Giuseppe ; Cervello, Melchiorre. / Emerging MEK inhibitors. In: Expert Opinion on Emerging Drugs. 2010 ; Vol. 15, No. 2. pp. 203-223.
@article{0f8006d7cee44f3ca521818a795e500c,
title = "Emerging MEK inhibitors",
abstract = "Importance of the field: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. Areas covered by this review: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series. What the reader will gain: By reading this review the reader will understand the important roles that genetics play in the response of patients to MEK inhibitors, the potential of combining MEK inhibitors with other types of therapy, the prevention of cellular aging and the development of cancer stem cells. Take home message: Targeting MEK has been shown to be effective in suppressing many important pathways involved in cell growth and the prevention of apoptosis. MEK inhibitors have many potential therapeutic uses in the suppression of cancer, proliferative diseases and aging.",
keywords = "Apoptosis, Cancer, ERK, Kinases, MEK, MEK inhibitors, Proliferative disorders, Protein phosphorylation, Signal transduction",
author = "McCubrey, {James A.} and Steelman, {Linda S.} and Abrams, {Steven L.} and Chappell, {William H.} and Suzanne Russo and Roger Ove and Michele Milella and Agostino Tafuri and Paolo Lunghi and Antonio Bonati and Franca Stivala and Ferdinando Nicoletti and Massimo Libra and Martelli, {Alberto M.} and Giuseppe Montalto and Melchiorre Cervello",
year = "2010",
month = "6",
doi = "10.1517/14728210903282760",
language = "English",
volume = "15",
pages = "203--223",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Emerging MEK inhibitors

AU - McCubrey, James A.

AU - Steelman, Linda S.

AU - Abrams, Steven L.

AU - Chappell, William H.

AU - Russo, Suzanne

AU - Ove, Roger

AU - Milella, Michele

AU - Tafuri, Agostino

AU - Lunghi, Paolo

AU - Bonati, Antonio

AU - Stivala, Franca

AU - Nicoletti, Ferdinando

AU - Libra, Massimo

AU - Martelli, Alberto M.

AU - Montalto, Giuseppe

AU - Cervello, Melchiorre

PY - 2010/6

Y1 - 2010/6

N2 - Importance of the field: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. Areas covered by this review: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series. What the reader will gain: By reading this review the reader will understand the important roles that genetics play in the response of patients to MEK inhibitors, the potential of combining MEK inhibitors with other types of therapy, the prevention of cellular aging and the development of cancer stem cells. Take home message: Targeting MEK has been shown to be effective in suppressing many important pathways involved in cell growth and the prevention of apoptosis. MEK inhibitors have many potential therapeutic uses in the suppression of cancer, proliferative diseases and aging.

AB - Importance of the field: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. Areas covered by this review: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series. What the reader will gain: By reading this review the reader will understand the important roles that genetics play in the response of patients to MEK inhibitors, the potential of combining MEK inhibitors with other types of therapy, the prevention of cellular aging and the development of cancer stem cells. Take home message: Targeting MEK has been shown to be effective in suppressing many important pathways involved in cell growth and the prevention of apoptosis. MEK inhibitors have many potential therapeutic uses in the suppression of cancer, proliferative diseases and aging.

KW - Apoptosis

KW - Cancer

KW - ERK

KW - Kinases

KW - MEK

KW - MEK inhibitors

KW - Proliferative disorders

KW - Protein phosphorylation

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=77952864300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952864300&partnerID=8YFLogxK

U2 - 10.1517/14728210903282760

DO - 10.1517/14728210903282760

M3 - Article

C2 - 20151845

AN - SCOPUS:77952864300

VL - 15

SP - 203

EP - 223

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -